Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 4
Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC
Julia Rotow, MD, explores the rationale, study design, and primary endpoints of the AVANZAR trial, which investigated the combination of datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin as a first-line treatment for patients with advanced non-small cell lung cancer lacking actionable mutations, and discusses the patient population most likely to benefit from this drug combination.
- Please discuss the rationale, study design, and key endpoints for the AVANZAR (Aggarwal et al. WCLC 2023) trial evaluating Dato-DXd + durvalumab and carboplatin for 1L treatment of patients with advanced NSCLC without actionable mutations.
- What is the rationale for this treatment approach?
- What data do you anticipate and how may findings impact the current/future treatment landscape?
- In which patients would this treatment strategy most appropriate/beneficial?